Coya Therapeutics (NASDAQ:COYA) Trading Up 3.4% - Should You Buy?

Key Points

• Coya Therapeutics' stock increased by 3.4% on Friday, trading at $5.49 with a total of 38,992 shares exchanged, a significant decline from its average daily volume.
• Equities analysts hold a positive outlook on the stock, with four analysts issuing a Buy rating and an average price target of $16.50, indicating substantial potential upside.
• The company's recent earnings report revealed a loss of ($0.36) EPS, missing estimates, with anticipated continued losses for the fiscal year.

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was up 3.4% during trading on Friday . The company traded as high as $5.68 and last traded at $5.49. Approximately 38,992 shares traded hands during trading, a decline of 58% from the average daily volume of 92,139 shares. The stock had previously closed at $5.31.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on COYA shares. Chardan Capital reaffirmed a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, September 17th. D. Boral Capital reissued a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Wednesday, September 17th. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, August 25th. Finally, Lake Street Capital assumed coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $16.50.

Coya Therapeutics Stock Performance

The business's 50 day moving average is $6.14 and its 200-day moving average is $6.00. The stock has a market cap of $91.82 million, a price-to-earnings ratio of -4.43 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.78 million. Sell-side analysts anticipate that Coya Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in Coya Therapeutics during the 4th quarter worth $74,000. Northern Trust Corp boosted its stake in Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. CM Management LLC boosted its stake in Coya Therapeutics by 25.0% during the 1st quarter. CM Management LLC now owns 200,000 shares of the company's stock worth $1,294,000 after purchasing an additional 40,000 shares during the last quarter. Dauntless Investment Group LLC purchased a new position in shares of Coya Therapeutics during the 1st quarter worth $1,083,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Coya Therapeutics during the 1st quarter worth $65,000. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.